{
    "ticker": "SAGE",
    "name": "Sage Therapeutics, Inc.",
    "description": "Sage Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative therapies to transform the lives of patients with brain health disorders. Founded in 2010 and headquartered in Cambridge, Massachusetts, Sage is at the forefront of neuroscience research, focusing on the development of novel treatments for conditions such as depression, postpartum depression, and other related mental health issues. The company's lead product, Zuranolone, has shown promising results in clinical trials for the treatment of major depressive disorder and postpartum depression, aiming to provide rapid relief of symptoms. Sage's unique approach leverages its expertise in neurobiology and pharmacology to discover and develop compounds that address unmet medical needs. The company is committed to advancing its pipeline of therapies through rigorous clinical studies and collaborations with leading research institutions. Sage Therapeutics strives not only to improve patient outcomes but also to change the way mental health conditions are treated, aiming for a broader acceptance of innovative approaches in the field of psychiatry.",
    "industry": [
        "Biopharmaceuticals",
        "Neuroscience"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2010",
    "website": "https://www.sagerx.com",
    "ceo": "Barry Greene",
    "social_media": {
        "twitter": "https://twitter.com/SageRx",
        "linkedin": "https://www.linkedin.com/company/sage-therapeutics/"
    },
    "investor_relations": "https://investors.sagerx.com",
    "key_executives": [
        {
            "name": "Barry Greene",
            "position": "CEO"
        },
        {
            "name": "Katherine M. Tully",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Zuranolone"
            ]
        }
    ],
    "seo": {
        "meta_title": "Sage Therapeutics, Inc. | Innovating Brain Health Therapies",
        "meta_description": "Explore Sage Therapeutics, Inc., a leader in developing transformative therapies for brain health disorders. Learn about Sage's innovative treatments and commitment to neuroscience.",
        "keywords": [
            "Sage Therapeutics",
            "Zuranolone",
            "Brain Health",
            "Biopharmaceuticals",
            "Mental Health",
            "Depression Treatment"
        ]
    },
    "faq": [
        {
            "question": "What does Sage Therapeutics specialize in?",
            "answer": "Sage Therapeutics specializes in developing innovative therapies for brain health disorders."
        },
        {
            "question": "What is Sage's lead product?",
            "answer": "Sage's lead product is Zuranolone, aimed at treating major depressive disorder and postpartum depression."
        },
        {
            "question": "Where is Sage Therapeutics located?",
            "answer": "Sage Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "When was Sage Therapeutics founded?",
            "answer": "Sage Therapeutics was founded in 2010."
        },
        {
            "question": "Who is the CEO of Sage Therapeutics?",
            "answer": "Barry Greene is the CEO of Sage Therapeutics, Inc."
        }
    ],
    "competitors": [
        "VRTX",
        "BIIB",
        "PTCT",
        "ACAD"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "REGN",
        "CELG"
    ]
}